BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment The phase 1 Trial of BKT-140/BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 BKT-140/BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014 [fusion_builder_r
BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment BKT-140/BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia. BKT-140/BL-8040 is expected to commence Phase 1 trial in stem cell mobilization in Q2 2014, and top-line results are expected in H2 2014.
Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia BKT-140/BL-8040 study published in Molecular Cancer Therapeutics. BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials are expected [...]
BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 in Immunotherapy BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014.
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment A phase 1/2 study will assess the effect of BKT-140/BL-8040 in combination with standard therapy.
Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing and re-epithelialization (BKT170 Project).
BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment The phase 1 trial of BKT-140/BL-8040 is expected to begin in Q3 2014, with results expected in late 2014 or early 2015. BKT-140/BL-8040 is also in Phase 2 for AML, with results expected in early 2015.
Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
